Fundraising Fox

Alchemab Therapeutics

7 known investors

alchemab.com β†—

Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals. The company develops protective antibody therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology.

AI & Machine LearningBiotechDeep TechHealthtech

Founders & leadership

JOJane Osbourn
Jane OsbournChief Executive OfficerVenture Partner at Dementia Discovery Fund

Investors Β· 7

SV Health Investorsβœ“ verifiedBoston Β· $1M – $20M
DCVC Bioβœ“ verifiedPalo Alto
RA Capitalβœ“ verifiedBoston
Dementia Discovery FundLondon
Lightstone VenturesPortola Valley
Ono Venture Investment, Inc.South San Francisco
DCVC (Data Collective)reportedPalo Alto Β· $5M – $25M

Frequently asked questions

What does Alchemab Therapeutics do?
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals. The company develops protective antibody therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology.
Who are Alchemab Therapeutics's investors?
Alchemab Therapeutics's investors include SV Health Investors, DCVC Bio, RA Capital, Dementia Discovery Fund, Lightstone Ventures, Ono Venture Investment, Inc., DCVC (Data Collective).